Background {#Sec1}
==========

The mechanism of KCl-stimulated vascular smooth muscle (VSM) contraction may involve Ca^2+^-dependent and Ca^2+^ sensitization pathways. Membrane depolarization by KCl increases Ca^2+^ influx via voltage-dependent Ca^2+^ channel receptors on VSM cells, leading to an increase in cytosolic free Ca^2+^ (\[Ca^2+^\]~i~). This increase in \[Ca^2+^\]~i~ activates Ca^2+^-calmodulin-dependent myosin light chain kinase, resulting in MLC phosphorylation and vascular contraction \[[@CR1]--[@CR4]\]. In addition to the Ca^2+^-dependent pathway, the Ca^2+^-induced Ca^2+^ sensitization pathway may also regulate MLC phosphatase (MLCP) through modulation of class II phosphoinositide 3 kinase α subunit (PI3K-C2α) and Rho kinase activity, which results in vascular contraction \[[@CR5]--[@CR8]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Schematic illustration of volatile anesthetics on Ca^2+^-induced Ca^2+^ sensitization. VSM = vascular smooth muscle, GPCR = G protein coupled receptor, G12/13 = 12/13 subunit of heterotrimeric G-protein; Gq = q subunit of heterotrimeric G-protein, PLC = phospholipase C, IP3 = inositol 1,4,5-triphosphate, DAG = diacylglycerol, PKC = protein kinase C, CPI-17 = PKC-potentiated inhibitory protein, KCl = potassium chloride, CaM = calmodulin, PI3K-C2α = Class II phosphoinositide 3 kinase α-isoform, Rho kinase = small GTPase ROCK II, MLC = myosin light chain, p-MLC = phosphorylated MLC, MLCK = MLC kinase, MLCP = MLC phosphatase, MYPT1/853 = myosin phosphatase target subunit Thr853, MYPT1/696 = myosin phosphatase target subunit Thr696, PP1 = catalytic subunit of Type 1 protein phosphatase, M20 = accessory 20 kDa subunit, Dotted line = inhibitory effect

PI3Ks are a ubiquitously expressed enzyme family that phosphorylates membrane inositol lipids and exert diverse biological activities \[[@CR9], [@CR10]\]. PI3Ks are divided into three main classes. VSM is known to express multiple PI3Ks, including the class I enzymes p110α and p110β, and class II enzymes PI3K-C2α and C2β \[[@CR11]\].

Several studies show that sevoflurane (SEVO) and isoflurane (ISO) can provide protection against ischemia-reperfusion injury via the PI3K/Akt pathway \[[@CR12]--[@CR15]\]. In contrast, volatile anesthetics can result in some complications, such as hypertension, particularly at higher concentrations. The mechanism may involve relaxation of VSM directly through intracellular signaling transduction pathways \[[@CR1], [@CR16]--[@CR18]\]. However, the exact mechanism is not fully understood.

We previously demonstrated that SEVO inhibited GTPγ S-stimulated Rho-Rho kinase-mediated vasoconstriction in isolated rat aortic VSM \[[@CR16]\]. We also revealed that SEVO attenuated Angiotensin II (Ang II)-induced vasoconstriction by reducing PKC phosphorylation without affecting \[Ca^2+^\]~i~ in VSM \[[@CR17]\]. We recently demonstrated that SEVO inhibited MLC, the PKC-potentiated inhibitory protein CPI-17, and myosin phosphatase target subunit MYPT1/Thr853 phosphorylation in response to Ang II. ISO also inhibited MLC phosphorylation in response to Ang II, which was associated with a decrease in MYPT1/Thr853, but not in CPI-17 phosphorylation. Neither SEVO nor ISO affected Ang II-induced phosphorylation of MYPT1/Thr696 \[[@CR18]\]. However, little information is available about the effect of SEVO and ISO on Ca^2+^-induced Ca^2+^ sensitization in regulating VSM contraction. The current study involved investigating the effects of volatile anesthetic modulation of PI3K subunit and Rho kinase activity on vasoconstriction in response to KCl in rat isolated aortic smooth muscle.

Methods {#Sec2}
=======

Vascular smooth muscle tissue preparation {#Sec3}
-----------------------------------------

This protocol was approved by Shandong University Animal Care and Use Committee and Qilu Hospital of Shandong University Medical Ethics Committee (No. KYLL-2013-51). Aortic rings and strips were prepared according to previous protocols \[[@CR16]--[@CR18]\]. Male Wistar rats (250--350 g) were anesthetized with halothane and euthanized by exsanguination from the common carotid artery. The descending thoracic aorta was carefully dissected, and adherent fat and connecting tissue were removed. The endothelium was removed by gentle rubbing of the internal surface with a stainless steel needle.

Isometric force measurement {#Sec4}
---------------------------

In this study, KCl (60 mM) was used as an agonist according to previous results \[[@CR7]\]. KCl-elicited tension was measured using isometric force methods as described previously \[[@CR16]--[@CR18]\]. Briefly, endothelium-denuded aortic rings were equilibrated under a resting tension of 3 g in Krebs bicarbonate solution (KBS) (in mmol/L, NaCl, 118.2; KCl, 4.6; CaCl~2~, 2.5; KH~2~PO~4~, 1.2; MgSO~4~, 1.2; NaHCO~3~, 24.8; and dextrose 10) at 37 °C and gassed with a mixture of 95 % (v/v) O~2~ and 5 % (v/v) CO~2~ with a fresh gas flow of 2 L/min. After 60 min equilibration, with the bathing fluid replaced every 20 min, the aortic rings were incubated with KCl (60 mM) to access their overall contractile responsiveness. Removal of the endothelium was confirmed with 3 × 10^−7^ M phenylephrine pre-contracted vessels that showed a lack of relaxation in the presence of 10^−5^ M acetylcholine. To examine the effect of anesthetics on KCl-induced contraction, six aortic rings from each individual rat (*n* = 7) were randomly exposed to 0, 1, 2, and 3 minimum alveolar concentration (MAC) of each anesthetic, 1 mM LY294002 (PI3K inhibitor), or 1 μM Y27632 (Rho kinase inhibitor) for 15 min before the addition of KCl (Fig. [2](#Fig2){ref-type="fig"}). Isometric force development in response to KCl was expressed as a percentage relative to that induced by KCl.Fig. 2The protocol of sevoflurane, isoflurane, LY294002 and Y27632 on KCl-induced contraction of rat aortic smooth muscle. X axis = Time (min), Y axis = Tension (g), W = wash, S = stop, ISO = isoflurane, SEVO = sevoflurane, MAC = minimum alveolar concentration, Y = Y27632, LY = LY294002, Phe = phenylephedrine, Ach = acetylcholine

SEVO or ISO was delivered into the gas mixture with a fresh gas flow of 2 L/min via a calibrated agent-specific vaporizer (Penlon, Abingdon, UK) to aerate the KBS with equivalent human MAC. The concentration of the resulting gas mixture was monitored and adjusted using an Atom 303 anesthetic agent monitor (Atom, Tokyo, Japan). Our previous data using the same experimental system indicated that the concentrations of SEVO or ISO in KBS measured by gas chromatography (Shimazu Seisakusho, Tokyo, Japan) were 0.17, 0.28, and 0.41 mM for gas concentrations of 1.7 % (1 MAC), 3.4 % (2 MAC), and 5.1 % (3 MAC) SEVO, respectively (*n* = 8--12) and 0.19, 0.39, and 0.56 mM for gas concentrations of 1.2 % (1 MAC), 2.3 % (2 MAC), and 3.5 % (3 MAC) ISO, respectively (*n* = 8--12), after 15 min of equilibration.

Phosphorylation of MYPT1, CPI-17, and MLC {#Sec5}
-----------------------------------------

For measurement of MYPT1, CPI-17, and MLC phosphorylation, the endothelium-denuded strips (approximately 3.5 cm in length) were bathed in oxygenated KBS and were equilibrated for 60 min before the start of the experiment. One strip was obtained from each animal.

Previous data demonstrated that KCl (60 mM) induced a rapid increase in MLC phosphorylation and reached peak levels approximately 5 min after exposure to KCl \[[@CR8]\]. Therefore, the later experiments were examined 5 min after the application of KCl. Aortic strips from different animals were incubated with 0 (control), 60 mM KCl, 1 MAC SEVO, 2 MAC SEVO, 1 mM LY294002, and 1 μM Y27632, or 0 (control), 60 mM KCl, 1 MAC ISO or 2 MAC ISO, 1 mM LY294002, and 1 μM Y27632 for 15 min without KCl or 5 min in the presence of KCl, and were quickly frozen with liquid nitrogen. Thereafter, protein phosphorylation was measured using western blotting analysis as described previously \[[@CR10]--[@CR12]\]. Briefly, the frozen strips were cut into small pieces and homogenized in ice-cold lysis buffer with 0.2 % (v/v) Triton X-100. Homogenates were centrifuged at 10,000 g for 30 min at 4 °C. The supernatants were assayed for protein concentration using the bicinchoninic acid method \[[@CR13]\] and subsequently used for detection of MYPT1, CPI-17, and MLC phosphorylation.

In each experiment, proteins (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12 % or 5 %) and transferred to nitrocellulose membranes. Membranes were incubated with anti-MLC, anti-CPI-17, anti-MYPT1/Thr696, anti-MYPT1/Thr853 (1:1000, 1:1000, 1:500, and 1:500, respectively), and antiphospho-MLC, antiphospho-CPI-17, antiphospho-MYPT1/Thr696, and antiphospho-MYPT1/Thr853 antibodies (1:1000, 1:1000, 1:500, and 1:500, respectively) for 2 h, followed by incubation with a horseradish peroxidase-conjugated antibody (1:2000) for 1 h \[[@CR12]\].

The densities of immunoreactive bands were detected using chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and were assessed with image analysis software (NIH Image 1.62; National Institute of Health, Bethesda, MD, USA). Bands with molecular weights of 17 kDa, 20 kDa, and 110 kDa were identified as CPI-17, MLC, and MYPT1, respectively. The ratios of phosphorylated to total CPI-17, MLC, and MYPT1 were used as an indicator of activation of each enzyme and expressed as the percentage relative to the baseline control level (referred to as 100 %).

Membrane translocation of PI3K and Rho kinase (Rock II) {#Sec6}
-------------------------------------------------------

For enzyme membrane translocation, PI3K and Rho kinase (Rock II) activity were measured using western blotting analysis as described previously \[[@CR16]\]. Briefly, the endothelium-denuded aortic strips were bathed in 20-mL organ chambers containing KBS solution. The strips were equilibrated for 60 min in control KBS, which was replaced every 20 min. To measure the dose effect of SEVO, ISO, and kinase inhibition on KCl-stimulated membrane translocation of PI3K or Rock II, some aortas were treated with either 1.7 % SEVO, 3.5 % SEVO, 1.2 % ISO, 2.3 % ISO, 1 mM LY294002, or 1 μM Y27632 for 15 min before exposure to KCl. After treatment with KCl for 5 min, the samples were then rapidly frozen with liquid nitrogen.

Frozen aortas were cut into small pieces and were homogenized in ice-cold lysis buffer containing 1 mM Tris/HCl, pH 7.5, 5.5 mM MgCl~2~, 100 mM NaCl, 2 mM EDTA, 1 mM 4-(2-aminoethyl) benzonesulfonyl fluoride, 20 μg/mL leupeptin, 20 μg/mL aprotinin, and 1 mM Na~3~VO~4~. Homogenates were centrifuged at 13,000 g for 15 min at 4 °C, and the supernatants were collected and centrifuged at 100,000 g for 30 min at 4 °C again. The supernatant (cytosolic fraction) was removed, and the pellet (membrane fraction) was re-suspended using the same lysis buffer. The protein concentrations of each fraction were determined using the bicinchoninic acid method \[[@CR19]\].

Equal amounts of total protein (30 μg) were used for every sample in each experiment. Proteins were separated by 7.5 % or 12 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred to a nitrocellulose membrane. The membrane was treated with anti-PI3K-p85α, anti-PI3K-C2α, and anti-Rock-II antibodies (1:200, 1:200, and 1:500, respectively) for 4 h, followed by incubation with a horseradish peroxidase-conjugated antibody (1:2000) for 1 h. Immunoreactive bands were detected using chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and were assessed with image analysis software (NIH image 1.62; National Institute of Health). The amount of PI3K-p85α, PI3K-C2α, and Rock-II on the membrane was expressed as a percentage of the total value (i.e., membrane fraction plus cytosolic fraction).

Materials and reagents {#Sec7}
----------------------

SEVO and ISO were purchased from Dainabot Company Limited (Osaka, Japan). Polyclonal antibodies against phospho-MLC (Thr18/Ser19), phospho-MYPT1 (Thr853), phospho-MYPT1 (Thr696), phospho-CPI-17 (Thr38), MLC2 (FL-172), MYPT1 (H-130), CPI-17 (H60), PI3K-p85α, and Rock-II, and the secondary antibody labeled with horseradish peroxidase (HRP) were all obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). PI3K-C2α was purchased from Abcam, Inc. (Tokyo, Japan). LY294002 was provided from Merck-Calbiochem Biosciences (Darmstadt, Germany). Y27632 was purchased from Calbiochem-Novabiochem Corporation (San Diego, CA, USA). All other reagents for experiments and western blotting were of analytical grade.

Statistical analysis {#Sec8}
--------------------

Data analyses were performed using the software program StatMate (Atoms, Tokyo, Japan). The sample size (*n*) refers to the number of rats from which the aortas were harvested. Data are presented as the mean ± standard deviation and were analyzed using the Dunnett test after analysis of variance for multiple comparison of isometric tension or protein phosphorylation. A *p*-value \< 0.05 was considered significant.

Results {#Sec9}
=======

KCl induced rapid contraction and reached a maximum level approximately 5 min after, which was sustained for more than 30 min in rat aortic rings (Fig. [2](#Fig2){ref-type="fig"}). SEVO and ISO attenuated KCl-induced contraction in a concentration-dependent manner, and the contraction was also suppressed by LY294002 (1 mM) and Y27632 (1 μM). There was no statistical difference between SEVO and ISO when comparing equipotent concentrations (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effects of sevoflurane and isoflurane on KCl-induced contraction in rat aortic smooth muscle. The aortas rings were incubated in the presence of 1.7 %, 3.4 %, 5.1 % sevoflurane (SEVO) or 1.2 %, 2.3 %, 3.5 % isoflurane (ISO), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. Isometric tension development in response to anesthetic or inhibitor was expressed as percentage relative to that induced by KCl. \* *P* \< 0.05, \*\* *P* \< 0.01 versus the value in the presence of KCl without anesthetics or inhibitor (*n* = 7, each)

Consistent with the change in isometric force measurements, SEVO and ISO also inhibited MLC phosphorylation in a concentration-dependent manner in response to KCl (Fig. [4](#Fig4){ref-type="fig"}). SEVO and ISO inhibited membrane translocation of PI3K-C2α (Fig. [5c and d](#Fig5){ref-type="fig"}) and Rock-II (Fig. [6](#Fig6){ref-type="fig"}), but not PI3K-p85 (Fig. [5a and b](#Fig5){ref-type="fig"}) in response to KCl in a concentration-dependent manner in rat aortas.Fig. 4Effects of sevoflurane and isoflurane on KCl-induced MLC phosphorylation in rat aortic smooth muscle. The aortas strips were incubated in the presence of 1.7 %, 3.4 % sevoflurane (SEVO) or 1.2 %, 2.3 % isoflurane (ISO), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. MLC phosphorylation development in response to anesthetic or inhibitor was expressed as percentage relative to that induced by KCl. \* *P* \< 0.05, \*\* *P* \< 0.01 versus the value in the presence of KCl without anesthetics or inhibitor, \#\# *P* \< 0.01 compared with the baseline without KCl (*n* = 7, each) Fig. 5Effects of sevoflurane and isoflurane on member translocation of PI3K-C2α and PI3K-p85 in response to KCl. The aortic strips were incubated in the presence of 0, 1.7 %, 3.4 % sevoflurane (SEVO), or 0, 1.2 %, 2.3 % isoflurane (ISO), or 10 uM, 1 mM LY294002 for 15 min before and during exposure to KCl. The amount of PI3K-p85α (A and B) and PI3K-C2α (C and D) on the membrane was expressed as a percentage of the total value (i.e., membrane fraction plus cytosolic fraction). \* *P* \< 0.05, \*\* *P* \< 0.01 versus the value in the presence of KCl, \#\# *P* \< 0.01 compared with the baseline without KCl (*n* = 7, each) Fig. 6Effects of sevoflurane and isoflurane on member translocation of Rho kinase (Rock II) in response to KCl. The aortic strips were incubated in the presence of 0, 1.2 %, 2.3 % isoflurane (ISO,A), or 0, 1.7 %, 3.4 % sevoflurane (SEVO,B), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. The amount of Rock-II on the membrane was expressed as a percentage of the total value (i.e., membrane fraction plus cytosolic fraction). \* *P* \< 0.05, \*\* *P* \< 0.01 versus the value in the presence of KCl, \# *P* \< 0.05 compared with the baseline without KCl (*n* = 7, each)

Both SEVO and ISO inhibited the phosphorylation MYPT1/Thr853 in response to KCl in a concentration-dependent manner (Fig. [7](#Fig7){ref-type="fig"}). Neither SEVO nor ISO affected the increase in the phosphorylation of MYPT1/Thr696 (Fig. [8](#Fig8){ref-type="fig"}) and CPI-17/Thr38 (Fig. [9](#Fig9){ref-type="fig"}) in response to KCl.Fig. 7Effects of sevoflurane and isoflurane on KCl-induced MYPT1/853 phosphorylation in rat aortic smooth muscle. The aortas strips were incubated in the presence of 1.7 %, 3.4 % sevoflurane (SEVO) or 1.2 %, 2.3 % isoflurane (ISO), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. MYPT1/853 phosphorylation development in response to anesthetic or inhibitor was expressed as percentage relative to that induced by KCl. \* *P* \< 0.05, \*\* *P* \< 0.01 versus the value in the presence of KCl without anesthetic or inhibitor, \#\# *P* \< 0.01 compared with the baseline without KCl (*n* = 7, each) Fig. 8Effects of sevoflurane and isoflurane on KCl-induced MYPT1/696 phosphorylation in rat aortic smooth muscle. The aortas strips were incubated in the presence of 1.7 %, 3.4 % sevoflurane (SEVO) or 1.2 %, 2.3 % isoflurane (ISO), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. MYPT1/696 phosphorylation development in response to anesthetic or inhibitor was expressed as percentage relative to that induced by KCl. \#\# *P* \< 0.01 compared with the baseline without KCl (*n* = 7, each) Fig. 9Effects of sevoflurane and isoflurane on KCl-induced CPI-17 phosphorylation in rat aortic smooth muscle. The aortas strips were incubated in the presence of 1.7 %, 3.4 % sevoflurane (SEVO) or 1.2 %, 2.3 % isoflurane (ISO), or 1 mM LY294002, or 1 uM Y27632 for 15 min before and during exposure to KCl. CPI-17 phosphorylation development in response to anesthetic or inhibitor was expressed as percentage relative to that induced by KCl. \* *P* \< 0.05 versus the value in the presence of KCl, \# *P* \< 0.05 versus the baseline without KCl (*n* = 7, each)

LY294002 (1 mM) inhibited KCl-induced PI3K-p85 and PI3K-C2α membrane translocation in response to KCl (*p* \< 0.05, p \< 0.01, respectively) (Fig. [5](#Fig5){ref-type="fig"}). In addition to Y27632 (1 μM), LY294002 (1 mM) also inhibited KCl-induced MLC phosphorylation (Fig. [4](#Fig4){ref-type="fig"}) and Rock-II membrane translocation in rat aortic smooth muscle (*p* \< 0.01) (Fig. [6](#Fig6){ref-type="fig"}).

Discussion and Conclusions {#Sec10}
==========================

The current study demonstrated that both SEVO and ISO inhibit KCl-induced MLC phosphorylation and vasoconstriction by modulating PI3K-C2α and Rho kinase activity in the rat aorta. These findings suggest that the inhibition of Ca^2+^-induced Ca^2+^ sensitization induced by volatile anesthetics contributes to its vasodilatory effect.

Several studies demonstrate that LY294002 and Y27632 inhibit KCl-induced vasoconstriction by suppressing MYPT1 and CPI-17 phosphorylation in rat or rabbit aortic smooth muscle \[[@CR8], [@CR11]\]. LY294002 is similar to the broad-spectrum PI3K inhibitor wortmannin, which inhibits class I PI3Ks (α, β, γ, and δ), class II PI3Ks, and class III PI3Ks \[[@CR20]\]. Previous studies have shown that the PI3K-C2α isoform is less sensitive to PI3K inhibitors compared with other PI3K isoforms \[[@CR21], [@CR22]\]. Therefore, we selected high concentrations of LY294002 to inhibit PI3K-C2α and MLC phosphorylation. In this study, our results showed that LY294002 and Y27632 inhibited KCl-induced vasoconstriction by suppressing MLC phosphorylation and contraction in rat aortic smooth muscle. We also demonstrated that LY294002 not only inhibits class II PI3K-C2α, but also class I PI3K-p85, as well as Rho kinase in response to KCl, suggesting that PI3K and/or Rho kinase may mediate the inhibition of KCl-induced Ca^2+^ sensitivity. Because specific PI3K-C2α-inhibitors do not exist, it remains unclear whether the reduced MLC phosphorylation and vasoconstriction depends on class II PI3K-C2α-inhibition or inhibition of class I PI3K.

Accumulating evidence demonstrates that PI3K-C2α and Rho kinase, or PKC, MYPT1/Thr853, and CPI-17 are involved in vasoconstriction by regulation of Ca^2+^-induced Ca^2+^ sensitization \[[@CR8], [@CR11], [@CR23]--[@CR25]\]. Previous data indicated that PKC is a major upstream activator of CPI-17 \[[@CR26], [@CR27]\]. Takuwa et al. reported that KCl membrane depolarization-induced CPI-17 phosphorylation was not inhibited by the protein kinase C inhibitor GF109203X \[[@CR25]\]. It seems likely that PKC was not involved in modulating KCl-induced CPI-17 phosphorylation. Rho kinase can regulate MLCP activity by influencing MYPT1 phosphorylation at Thr853 and/or Thr696 \[[@CR20]\]. It is possible that the inhibitory effect of SEVO and ISO on KCl-induced vasoconstriction was mainly mediated through the Ca^2+^/PI3K-C2α/Rho kinase/MYPT1/Thr853 pathway.

Several reports also showed that SEVO decreased myofilament Ca^2+^ sensitivity by regulating Rho kinase and PKC activity \[[@CR1], [@CR17], [@CR18]\]. We recently showed that SEVO does not alter norepinephrine-induced intracellular Ca^2+^ changes in the diabetic rat aorta \[[@CR28]\]. These data further demonstrate that myofilament Ca^2+^ sensitization, not Ca^2+^-dependent mechanisms, is involved in modulating vascular tension by SEV.

Evidence also demonstrates that ISO inhibition of agonist-induced contraction of Ca^2+^ sensitivity mechanisms is mainly mediated by increasing Ca^2+^ influx via voltage-dependent calcium channels \[[@CR29], [@CR30]\]. We previously demonstrated that ISO exhibited no inhibitory effect on PKC phosphorylation in response to Ang II up to a concentration of 3.5 % \[[@CR31]\]. These data indicate that ISO-regulated vasoconstriction is mainly through the Ca^2+^-dependent pathway and not through the Ca^2+^ sensitivity pathway. In contrast to the above results, we recently demonstrated that ISO inhibits Ang II-induced vasoconstriction through regulating the phosphorylation of the MLCP subunit MYPT1/Thr853 \[[@CR18]\]. Furthermore, we demonstrated that ISO inhibits KCl-elicited MLC phosphorylation and vasoconstriction by suppressing MYPT1/Thr853, and not CPI-17 phosphorylation in the rat aorta. These data show that the Ca^2+^-induced Ca^2+^ sensitization pathway was also involved in the regulation of vasoconstriction by ISO.

Overall, our data, in combination with other investigations, reveal that inhibition of KCl-elicited vasoconstriction by volatile anesthetics may involve the modulation of PI3K-C2α and/or Rho-Rho kinase activity, the upstream activators of MLCP \[[@CR8], [@CR11], [@CR25]\]. Consistent with these data, the current investigation confirmed that both SEVO and ISO suppress the vasoconstriction of Ca^2+^-induced Ca^2+^ sensitization through modulating PI3K-C2α, Rho kinase activity, and MYPT1/Thr853 phosphorylation in rat vascular smooth muscle.

However, this study has some limitations: (1) the aim of this study was to elucidate the cellular mechanisms responsible for anesthetic-induced inhibition of vasoconstriction. Therefore, we used endothelium-denuded aortic strips or rings for this study. Indeed, the endothelium plays an important role in regulating systemic vascular tone under *in vivo* conditions. However, we used endothelium-denuded samples to avoid the effects of the endothelium. (2) Moreover, pre-arteriolar resistance arteries, not conduit arteries, mainly determine peripheral vascular resistance. Therefore, the current results obtained from endothelium-denuded aortas cannot be used to directly extrapolate to the *in vivo* condition. (3) Furthermore, the aortic rings are not necessarily reflective of the physiology of resistance arteries and thus may not be ideally suited to address issues related to the clinical hemodynamic effects of volatile anesthetics.

In conclusion, our study demonstrates that both SEVO and ISO inhibit KCl-induced PI3K-C2α-participation, Rho kinase-mediated MLC phosphorylation, and vasoconstriction in rat aortic smooth muscle. The intracellular mechanisms of regulating VSM contraction of volatile anesthetics may be mediated by the KCl/PI3K-C2α/Rho kinase/MLCP/MLC pathway.

Abbreviations {#Sec11}
=============

Ang II, Angiotensin II; BCA, bicinchoninic acid; CaM, Ca2 + -calmodulin; CPI-17/Thr38, PKC-potentiated inhibitory protein/Thr38; GPCR, G protein-coupled receptors; ISO, isoflurane; MAC, minimum alveolar concentration; MLC, myosin light chain; MLCK, myosin light chain kinase; MLCP, MLC phosphatase; MYPT1/Thr696, myosin phosphatase target subunit/Thr696; MYPT1/Thr853, myosin phosphatase target subunit/Thr853; PI3K-C2α, Class II phosphoinositide 3-kinase α-isoform; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEVO, sevoflurane; VSM, vascular smooth muscle

The present study was supported by the National Natural Science Foundation of China (No. 81171864), and the Fundamental Research Funds of Shandong University of China (No. 2014YQ014). The authors also thank Koji Ogawa M.D. and Yasuyuki Tokinaga M.D. (Department of Anesthesiology, Wakayama Medical University of Japan) for their experimental guidance of this manuscript.

Availability of data and materials {#FPar1}
==================================

For all journals, BioMed Central strongly encourages all datasets on which the conclusions of the manuscript rely to be either deposited in publicly available repositories (where available and appropriate) or presented in the main paper or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible.

In this article detailing where the data supporting their findings can be found.

Authors' contributions {#FPar2}
======================

SZY & QW data mining, analysis and part of statistical analysis. ZW & SSH part of experimental design. FQ ideal conception, data analysis and paper writing. All authors read and approved the final version of the manuscript.

Competing interests {#FPar3}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar4}
=======================

If your manuscript contains any individual person's data in any form (including individual details, images or videos), consent to publish must be obtained from that person, or in the case of children, their parent or legal guardian.

My manuscript does not contain any individual persons data, we state "Not applicable" in this section.

The authors agree to conditions of submission, BioMed Central\'s copyright and license agreement and article-processing charge (APC).

Ethics approval and consent to participate {#FPar5}
==========================================

This protocol was approved by Shandong University Animal Care and Use Committee and Qilu Hospital of Shandong University Medical Ethics Committee (No. KYLL-2013-051).
